Health Blueprint

Back to Longevity News

News summary

Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint, SINTBILO® (Tafolecimab Injection) as First-line Monotherapy Treatment for Hyperlipidemia Demonstrated Potent Lipid-lowering Efficacy

Source: PR Newswire • Published: 09 Nov 2026, 00:00

Summarized by Masters of Longevity from PR Newswire.

Tafolecimab monotherapy significantly reduced LDL-C versus placebo at week 12.

Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint, SINTBILO® (Tafolecimab Injection) as First-line Monotherapy Treatment for Hyperlipidemia Demonstrated Potent Lipid-lowering Efficacy
Key Takeaways
  • Tafolecimab reduced LDL-C by a clinically meaningful amount.
  • It also lowered Lp(a) and other lipid risk factors.
  • The study was in Chinese patients and was not causal.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.MoL PickReducing Inflammation from Ageing Cells: What a Mouse Study FoundResearchers reduced the inflammatory signals released by cells that had stopped dividing. Older mice also improved on some strength and frailty tests. Whether this approach could help people remains unknown.